Compare IVVD & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVVD | AVXL |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.9M | 237.2M |
| IPO Year | 2021 | 2013 |
| Metric | IVVD | AVXL |
|---|---|---|
| Price | $0.61 | $2.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $8.75 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 5.2M | 1.3M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 79.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,426,000.00 | N/A |
| Revenue This Year | $61.57 | N/A |
| Revenue Next Year | $41.42 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 110.47 | N/A |
| 52 Week Low | $0.49 | $2.26 |
| 52 Week High | $3.07 | $13.99 |
| Indicator | IVVD | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 28.31 | 47.91 |
| Support Level | N/A | $2.41 |
| Resistance Level | $1.01 | $2.80 |
| Average True Range (ATR) | 0.08 | 0.16 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.97 | 51.40 |
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.